• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    23.76 +2.64 (+12.50%)
    Streaming Delayed Price Updated: 2:18 PM EDT, Apr 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,886,183
    Open 21.26
    Bid (Size) 23.71 (700)
    Ask (Size) 23.81 (1,200)
    Prev. Close 21.12
    Today's Range 21.26 - 24.54
    52wk Range 13.83 - 36.91
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
    The next 10 months might be challenging for this biotech. 
    Via The Motley Fool

    Performance

    YTD
    +35.6%
    +35.6%
    1 Month
    +46.9%
    +46.9%
    3 Month
    +34.6%
    +34.6%
    6 Month
    +4.9%
    +4.9%
    1 Year
    -3.5%
    -3.5%

    More News

    Read More
    News headline image
    Summit Therapeutics to Present at Upcoming Investor Conferences
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics (NASDAQ:SMMT) Reports Widening Q4 Losses Amid Aggressive Clinical Push ↗
    Via Chartmill
    News headline image
    Summit (SMMT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens ↗
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    Is SharpLink Gaming Stock a Buy or Sell After Apeiron Capital Sold Its Stake Valued at $23 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    2 Stocks That Could Soar This Year ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
    From Summit Therapeutics
    Via Business Wire
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    News headline image
    2 Biotech Stocks That Could Soar This Year ↗
    Via The Motley Fool
    News headline image
    Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Summit Therapeutics Inc. - Common Stock publicly traded?
    Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Summit Therapeutics Inc. - Common Stock trade on?
    Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
    The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
    What is the current price of Summit Therapeutics Inc. - Common Stock?
    The current price of Summit Therapeutics Inc. - Common Stock is 23.76
    When was Summit Therapeutics Inc. - Common Stock last traded?
    The last trade of Summit Therapeutics Inc. - Common Stock was at 04/16/26 02:18 PM ET
    What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
    The market capitalization of Summit Therapeutics Inc. - Common Stock is 2.31B
    How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
    Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.